What is US 8,158,616 B2, and how is it connected to baricitinib?
US 8,158,616 B2 is a patent record that the DrugPatentWatch.com database tracks in connection with baricitinib (sold as Olumiant). [1]
DrugPatentWatch links patent documentation to the drug’s IP landscape, helping you see which patents are listed against baricitinib and related filings. [1]
Who holds US 8,158,616 B2, and what does it cover?
DrugPatentWatch’s baricitinib pages are typically where the patent owner/assignee and the patent’s publication/coverage details are summarized for users searching the IP landscape. [1]
If you want, paste the DrugPatentWatch link you’re looking at (or the assignee name shown on your end), and I can help interpret the specific claim scope and how it would affect baricitinib exclusivity or generic entry.
How long does patent protection last for baricitinib if this is one of the listed patents?
The effective protection timeline depends on the patent’s priority date and whether it has any extensions, plus other overlapping patents (not just one). DrugPatentWatch is one of the places that consolidates this “baricitinib patents by status” view. [1]
Why are people searching this baricitinib patent number (generic/biosimilar, challenges, licensing)?
Searches for a specific patent number like US 8,158,616 B2 are usually tied to:
- planning generic entry around expiration dates,
- assessing whether a company might challenge the patent,
- identifying licensing or settlement risk if exclusivity is near expiry.
DrugPatentWatch is designed for that kind of patent-by-drug research workflow. [1]
Can you share what you need from the patent (expiry, claims, owner, litigation)?
US 8,158,616 B2 can be used in different ways depending on your goal. Tell me what you’re trying to find:
- expiration/earliest expiry date,
- patent owner/assignee,
- claim theme (what the invention actually covers),
- whether it’s been invalidated/overcome (litigation status),
- or whether it’s listed for baricitinib specifically vs. a related compound/formulation.
Sources:
1. DrugPatentWatch.com – baricitinib patent information (includes US 8,158,616 B2)